Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Khiron Life Sciences Corp. (V:KHRN)

Business Focus: Alternative Medicine

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for KHRN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 29, 2021 08:30 ET
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early
Read full article
Jul 29, 2021 08:30 ET
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.02
--
--
Price to Sales - TTM
6.20
12.06
12.91
Price to Book - most recent quarter
0.85
2.94
3.58
Price to Cash Flow per share - TTM
--
13.74
18.29
Price to Free Cash Flow per share - TTM
--
14.88
29.01
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 20213,201,2122,937,206
Jun 30, 2021264,006187,935
Jun 15, 202176,071-11,709
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Khiron Life Sciences Corp, formerly Adent Capital Corp, is a Canada-based company engaged in alternative medicine sector. The Company is an integrated medical cannabis company with its core operations in Latin America. Khiron is active in the research area in medical cannabis industry. It develops and commercializes medical cannabis products mainly in Colombia.

See business summary

 

Twitter

Search (past week) for $KHRN.CA KHRN.V